insights_auto
Bakit bumaba ang ABVX 3.11%?
Tingnan ang Higit pang Detalyechevron_right
ABVX:EPA
Abivax SA
€80.90
arrow_downward
-3.11%(-2.60) 1D
Okt 5, 5:35:21 PM GMT+2 · EUR
search
Lahat ng simbolo
| Simbolo | Presyo | Palitan | % ng Pagbabago |
|---|
insights_autoBumubuo ng mga nangungunang insight para sa ABVX...
Buksan
€83.40
Mataas
€83.40
Mababa
€79.85
Mkt. cap
7.08B
Avg. na dami
155.90K
Dami
99.15K
Mataas nang 52-wk
€139.00
Mababa nang 52-wk
€60.45
EPS
-€5.20
Mga natitirang share
87.53M
Bilang ng mga empleyado
98
Buksan
€83.40
Mataas
€83.40
Mababa
€79.85
Mkt. cap
7.08B
Avg. na dami
155.90K
Dami
99.15K
Mataas nang 52-wk
€139.00
Mababa nang 52-wk
€60.45
EPS
-€5.20
Mga natitirang share
87.53M
Bilang ng mga empleyado
98
Mga balita at kwento
Mula sa mga source sa web at partner sa balita
Reuters
·
2 oras ang nakalipas
S&P 500 up, Nasdaq at record high as megacap tech stocks rise
AP News
·
4 araw ang nakalipas
France’s public debt hits records as economy takes center stage in French election
Goldman Sachs
·
1 linggo ang nakalipas
Can AI Investment Drive S&P 500 Earnings Even Higher?
MarketWatch
·
3 araw ang nakalipas
The stock market is anything but normal right now — and these charts show it
Profile
Abivax SA is a clinical stage biotechnology company focused on developing innovative treatments that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases.
Abivax has a program in clinical development with its lead drug candidate, obefazimod, to treat ulcerative colitis. Another program in Crohn’s disease is also in preparation and other potential inflammatory indications are being evaluated.
The company’s headquarters are based in Paris, France with a US office in Waltham, Massachusetts. Abivax’s Research and development work is conducted at its research center based in Montpellier, France. Wikipedia
Tungkol sa Abivax SA
CEOMarc de Garidel | Hartmut J. Ehrlich
Mga Empleyado98
ItinatagDis 4, 2013
Headquarters-
Sektor-
Websiteabivax.com